CJC-1295: Benefits, How to Use It, and Side Effects

CJC-1295

Also known as: CJC-1295 with DAC, Modified GRF 1-29 (CJC-1295 without DAC)

A synthetic analog of growth hormone releasing hormone (GHRH) that raises baseline growth hormone and IGF-1 levels, commonly stacked with ipamorelin in the peptide community.

Check current pricing at Amino Club

Affiliate link — shop CJC-1295. We may earn a commission at no cost to you.

What Is CJC-1295?

TL;DR: CJC-1295 is a synthetic GHRH analog that raises baseline growth hormone and IGF-1 levels — it comes in a short-acting and a long-acting (“with DAC”) version, and is almost always discussed together with ipamorelin.

CJC-1295 is a modified, more stable version of growth hormone releasing hormone (GHRH), the natural hormone that signals the pituitary gland to produce and release growth hormone. The “DAC” (Drug Affinity Complex) modification allows the peptide to bind reversibly to albumin in the bloodstream, protecting it from rapid breakdown and extending its effective half-life from a few minutes to several days.

How It Works

By mimicking GHRH, CJC-1295 signals the pituitary gland to increase its baseline production and release of growth hormone, which in turn raises circulating IGF-1 (insulin-like growth factor 1) — the hormone most directly responsible for GH’s tissue-building effects.

Who Uses It and Why

CJC-1295 is popular among the same audiences drawn to ipamorelin — people interested in body composition, recovery, and general GH-axis support — and the two are frequently stacked together specifically because of their complementary mechanisms.

Reported Benefits

Sustained increase in GH and IGF-1

CJC-1295 is a modified analog of growth hormone releasing hormone (GHRH). Clinical pharmacology studies (in the version with Drug Affinity Complex, or DAC) showed sustained elevations in growth hormone and IGF-1 levels for days after a single injection, due to the DAC component binding to albumin in the blood and extending the peptide's half-life.

Complementary effect with GHRPs

Because CJC-1295 raises the overall baseline of GH release rather than triggering a sharp pulse, it's commonly paired with a ghrelin-receptor agonist like ipamorelin, which triggers the pulse — the community reports this combination produces a bigger combined effect on GH than either used alone.

Body composition and recovery support

As with other GH secretagogues, reported benefits center on the downstream effects of elevated GH/IGF-1 — support for lean mass, fat metabolism, and tissue recovery — rather than a direct action of CJC-1295 itself.

How CJC-1295 Is Typically Used

Common forms

Subcutaneous injection

Typical protocol discussed in the community

CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life and is typically dosed daily, often alongside ipamorelin. CJC-1295 with DAC has a much longer half-life and is sometimes dosed just once or twice a week in community protocols. These are anecdotal regimens, not clinical dosing guidelines.

Notes

The 'with DAC' and 'without DAC' versions behave quite differently due to the half-life difference, and are frequently confused with each other when comparing user-reported protocols — always confirm which version a given source is describing.

Legal Status

Not FDA-approved for human use. Sold in the U.S. as a research chemical labeled 'not for human consumption.'

Potential Side Effects

Injection site reactions
Flushing, especially with DAC versions
Water retention
Headache
Joint discomfort (theorized to be linked to elevated IGF-1)
Unknown long-term safety profile from unsupervised human use

Frequently Asked Questions

What's the difference between CJC-1295 with and without DAC?+

DAC (Drug Affinity Complex) is a modification that lets the peptide bind to albumin in the bloodstream, dramatically extending its half-life from minutes (without DAC) to several days (with DAC). This changes dosing frequency significantly — without DAC is usually dosed daily, while with DAC can be dosed much less often.

Why do people combine CJC-1295 with ipamorelin?+

The two peptides work on different receptors involved in GH release — CJC-1295 mimics GHRH to raise the overall baseline, while ipamorelin mimics ghrelin to trigger a distinct pulse. The community reports the combination produces a stronger, more synergistic effect than either peptide alone.

Does CJC-1295 increase IGF-1 levels measurably?+

Clinical pharmacology studies of the DAC version did show measurable, sustained increases in IGF-1 following dosing, which is part of why it's of interest to researchers studying GH axis modulation.